Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services, Business & People, Manufacturers & Providers

TITLE:

NMMDA informs Healthcare Professionals with regard to safety issues associated with treatment with Thalidomide Celgene (thalidomide)

BRIEF:

According to a direct communication to Healthcare Professionals issued by Celgene Europe Limited and recently published on the website of the National Medicines and Medical Devices Agency (NMMDA), cases of viral activation especially in patients with a history of herpes zoster virus infection or hepatitis b were reported, following treatment with Thalidomide Celgene 50 mg capsule (thalidomide).

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company